NDRG2 is a candidate tumor-suppressor for oral squamous-cell carcinoma

Biochemical and Biophysical Research Communications

Volumn 391, Issue 4, 2010, Pages 1785-1791

  Furuta, Hiroshi ^a,b   Kondo, Yuudai ^a,b   Nakahata, Shingo ^b   Hamasaki, Makoto ^b   Sakoda, Sumio ^a   Morishita, Kazuhiro ^b  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Methylation; N myc downstream regulated gene 2; Oral squamous cell carcinoma; PI3K Akt signaling

Indexed keywords

AGAR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; DYSPLASIA; ENZYME ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; METHYLATION; MOUTH CARCINOMA; N MYC DOWNSTREAM REGULATED GENE 2; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA METHYLATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOUTH NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR SUPPRESSOR PROTEINS;

EID: 74449083873     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.156     Document Type: Article

References (32)

1. Shah J.P., and Singh B. Keynote comment: why the lack of progress for oral cancer?. Lancet Oncol. 7 (2006) 356-357
2. Nomura K., Sobue T., Nakatani H., et al. Number of deaths and proportional mortality rates from malignant neoplasms by site in Japan (2003). The Editorial Board of the Cancer Statistics in Japan. Cancer Statistics in Japan 2005 (2005), National Cancer Center, Tokyo 36-39
3. Gibson M.K., and Forastiere A.A. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol. 7 (2006) 565-574
4. Molinolo A.A., Amornphimoltham P., Squarize C.H., et al. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 45 (2009) 324-334
5. Ha P.K., and Califano J.A. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol. 7 (2006) 77-82
6. Ogi K., Toyota M., Ohe-Toyota M., et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin. Cancer Res. 8 (2002) 3164-3171
7. Boulkroun S., Fay M., Zennaro M.C., et al. Characterization of rat NDRG2 (N-Myc downstream regulated gene 2), a novel early mineralocorticoid-specific induced gene. J. Biol. Chem. 277 (2002) 31506-31515
8. Qu X., Zhai Y., Wei H., et al. Characterization and expression of three novel differentiation-related genes belong to the human NDRG gene family. Mol. Cell Biochem. 229 (2002) 35-44
9. Zhang J., Li F., Liu X., et al. The repression of human differentiation-related gene NDRG2 expression by Myc via Miz-1-dependent interaction with the NDRG2 core promoter. J. Biol. Chem. 281 (2006) 39159-39168
10. Piepoli A., Cotugno R., Merla G., et al. Promoter methylation correlates with reduced NDRG2 expression in advanced colon tumour. BMC Med. Genomics 2 (2009) 11
11. Kim Y.J., Yoon S.Y., Kim J.T., et al. NDRG2 expression decreases with tumor stages and regulates TCF/beta-catenin signaling in human colon carcinoma. Carcinogenesis 30 (2009) 598-605
12. Tepel M., Roerig P., Wolter M., et al. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int. J. Cancer 123 (2008) 2080-2086
13. Choi S.C., Yoon S.R., Park Y.P., et al. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp. Mol. Med. 39 (2007) 705-714
14. Lee D.C., Kang Y.K., Kim W.H., et al. Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res. 68 (2008) 4210-4220
15. Lusis E.A., Watson M.A., Chicoine M.R., et al. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res. 65 (2005) 7121-7126
16. Liu N., Wang L., Liu X., et al. Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem. Biophys. Res. Commun. 358 (2007) 164-169
17. Deng Y., Yao L., Chau L., et al. N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int. J. Cancer 106 (2003) 342-347
18. Park Y., Shon S.K., Kim A., et al. SOCS1 induced by NDRG2 expression negatively regulates STAT 3 activation in breast cancer cells. Biochem. Biophys. Res. Commun. 363 (2007) 361-367
19. Lim J., Kim J.H., Paeng J.Y., et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J. Clin. Pathol. 58 (2005) 1199-1205
20. Pedrero J.M., Carracedo D.G., Pinto C.M., et al. Frequent genetic and biochemical alterations of the PI3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer 114 (2005) 242-248
21. Amornphimoltham P., Sriuranpong V., Patel V., Benavides F., Conti C.J., Sauk J., et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin. Cancer Res. 10 (2004) 4029-4037
22. Pedrero J.M., Carracedo D.G., Pinto C.M., et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int. J. Cancer 114 (2005) 242-248
23. Chen W.Q., Hoeger H., Diao W.F., et al. Mass spectrometrical characterization of NDRG2 protein (N-myc-downstream regulated gene 2) and description of two novel phosphorylation sites. Neurochem. Res. 32 (2007) 1969-1977
24. Burchfield J.G., Lennard A.J., Narasimhan S., et al. Akt mediates insulin-stimulated phosphorylation of Ndrg2: evidence for cross-talk with protein kinase C theta. J. Biol. Chem. 279 (2004) 18623-18632
25. Liu N., Wang L., Li X., et al. N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis. Nucleic Acids Res. 36 (2008) 5335-5349
26. Wang L., Liu N., Yao L., et al. NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells. Cell Physiol. Biochem. 21 (2008) 239-250
27. Gupta A.K., McKenna W.G., Weber C.N., et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res. 8 (2002) 885-892
28. Ongkeko W.M., Altuna X., Weisman R.A., and Wang-Rodriguez J. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am. J. Clin. Pathol. 124 (2005) 71-76
29. Massarelli E., Liu D.D., Lee J.J., et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer 104 (2005) 2430-2436
30. Yu Z., Weinberger P.M., Sasaki C., et al. Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 553-558
31. Sheu J.J., Hua C.H., Wan L., et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res. 69 (2009) 2568-2576
32. Bussink J., van der Kogel A.J., and Kaanders J.H. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 9 (2008) 288-296